Please assess the completion status of the following clinical trial:

Trial Title: CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Metastatic or unresectable measurable cancers that express mesothelin. As in other protocols conducted by Dr. Hassan in the National Cancer Institute (NCI), epithelial mesotheliomas and pancreatic cancers do not need to be assessed for mesothelin expression since all of these tumors have been shown to express mesothelin. Other metastatic or unresectable cancers must be shown to expresses mesothelin as assessed by reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry on tumor tissue. Bi-phasic mesotheliomas must express mesothelin on greater than 50% of the cells in the epithelial component. Diagnosis will be confirmed by the Laboratory of Pathology, NCI.~ 2. Patients must have previously received at least one systemic standard care (or effective salvage chemotherapy regimens) for metastatic or unresectable disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred.~ 3. Greater than or equal to 18 years of age and less than or equal to 70 years of age.~ 4. Willing to sign a durable power of attorney~ 5. Able to understand and sign the Informed Consent Document~ 6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.~ 7. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment.~ 8. Serology:~     1. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)~    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be Hepatitis C virus ribonucleic acid (HCV RNA) negative.~ 9. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.~ 10. Hematology:~      1. Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim.~     2. White blood cell (WBC) (\> 3000/mm(3)).~     3. Platelet count greater than 100,000/mm(3).~     4. Hemoglobin greater than 8.0 g/dl.~ 11. Chemistry:~      1. Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) less or equal to 2.5 times the upper limit of normal.~     2. Serum creatinine less than or equal to 1.6 mg/dl.~     3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.~ 12. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patient's toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).~      Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.~ 13. Subject's must be co-enrolled in protocol 03-C-0277.~EXCLUSION CRITERIA:~1. Patients with sarcomatoid mesothelioma as mesothelin is not expressed in this type of mesothelioma.~2. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.~3. Patients with known brain metastases.~4. Patients receiving full dose anticoagulative therapy.~5. Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnesses.~6. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).~7. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).~8. Patients with diabetic retinopathy.~9. Concurrent Systemic steroid therapy.~10. History of severe immediate hypersensitivity reaction to any of the agents used in this study.~11. History of coronary revascularization or ischemic symptoms.~12. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45% tested in patients with:~    * Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block, chest pain, or ischemic heart disease~   * Age greater than or equal to 65 years old~13. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted tested in patients with:~    * A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years).~   * Symptoms of respiratory dysfunction~14. Patients who are receiving any other investigational agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1/Phase I (Type: EXPERIMENTAL): Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
- 2/Phase II (Type: EXPERIMENTAL): Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin

Based on this trial design, predict the completion outcome and termination type (if applicable).